Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.0123 EUR
63.60 M EUR
816.91 M EUR
2.03 B
About Luye Pharma Group Ltd.
Sector
Industry
CEO
Dian Bo Liu
Website
Headquarters
Guangzhou
Founded
1994
ISIN
BMG570071099
FIGI
BBG006SC41J2
Luye Pharma Group Ltd. is an investment holding company, which engages in the developing, producing, marketing, and selling of pharmaceutical products. It operates through the following segments: Oncology Drugs, Cardiovascular System Drugs, Alimentary Tract and Metabolism Drugs, Central Nervous System Drugs, and Others. The company was founded on June 8, 1994 and is headquartered in Yantai, China.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Luye Pharma Group Ltd. stocks are traded under the ticker LUP.
We've gathered analysts' opinions on Luye Pharma Group Ltd. future price: according to them, LUP price has a max estimate of 0.55 EUR and a min estimate of 0.41 EUR. Watch LUP chart and read a more detailed Luye Pharma Group Ltd. stock forecast: see what analysts think of Luye Pharma Group Ltd. and suggest that you do with its stocks.
Yes, you can track Luye Pharma Group Ltd. financials in yearly and quarterly reports right on TradingView.
Luye Pharma Group Ltd. is going to release the next earnings report on Apr 1, 2026. Keep track of upcoming events with our Earnings Calendar.
LUP earnings for the last half-year are 0.01 EUR per share, whereas the estimation was 0.01 EUR, resulting in a 18.86% surprise. The estimated earnings for the next half-year are 0.01 EUR per share. See more details about Luye Pharma Group Ltd. earnings.
Luye Pharma Group Ltd. revenue for the last half-year amounts to 376.85 M EUR, despite the estimated figure of 357.81 M EUR. In the next half-year revenue is expected to reach 401.36 M EUR.
LUP net income for the last half-year is 36.33 M EUR, while the previous report showed 11.33 M EUR of net income which accounts for 220.58% change. Track more Luye Pharma Group Ltd. financial stats to get the full picture.
Luye Pharma Group Ltd. dividend yield was 0.00% in 2024, and payout ratio reached 0.00%. The year before the numbers were 0.00% and 0.00% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 19, 2025, the company has 5.15 K employees. See our rating of the largest employees — is Luye Pharma Group Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Luye Pharma Group Ltd. EBITDA is 252.30 M EUR, and current EBITDA margin is 32.07%. See more stats in Luye Pharma Group Ltd. financial statements.
Like other stocks, LUP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Luye Pharma Group Ltd. stock right from TradingView charts — choose your broker and connect to your account.